Avidity Biosciences, Inc.
RNA
$26.57
-$1.53-5.45%
| Weiss Ratings | RNA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | RNA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Fair | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | RNA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.54 | |||
| Price History | RNA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -17.10% | |||
| 30-Day Total Return | -14.62% | |||
| 60-Day Total Return | -13.71% | |||
| 90-Day Total Return | -37.57% | |||
| Year to Date Total Return | -14.79% | |||
| 1-Year Total Return | 12.16% | |||
| 2-Year Total Return | 86.46% | |||
| 3-Year Total Return | 29.61% | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -49.82% | |||
| 52-Week Low % Change | 30.33% | |||
| Price | RNA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $56.00 | |||
| 52-Week Low Price | $21.56 | |||
| 52-Week Low Price (Date) | Apr 04, 2024 | |||
| 52-Week High Price (Date) | Nov 13, 2024 | |||
| Valuation | RNA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 3.38B | |||
| Enterprise Value | 1.88B | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -2.90 | |||
| Earnings Per Share Growth | -0.17% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 331.37 | |||
| Price/Book (Q) | 2.36 | |||
| Enterprise Value/Revenue (TTM) | 172.82 | |||
| Price | $26.57 | |||
| Enterprise Value/EBITDA (TTM) | -5.01 | |||
| Enterprise Value/EBIT | -4.97 | |||
| Market Cap Category | Mid Cap | |||
| Dividends and Shares | RNA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 128.50M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | RNA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 858 401 7900 | |||
| Address | 10578 Science Center Drive San Diego, CA 92121 | |||
| Website | www.aviditybiosciences.com | |||
| Country | United States | |||
| Year Founded | 2012 | |||
| Profitability | RNA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -3,477.44% | |||
| Profit Margin | -2,957.72% | |||
| Management Effectiveness | RNA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -21.60% | |||
| Return on Equity | -- | |||
| Income Statement | RNA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 10.90M | |||
| Total Revenue (TTM) | 10.90M | |||
| Revenue Per Share | $0.09 | |||
| Gross Profit (TTM) | -292.70M | |||
| EBITDA (TTM) | -376.16M | |||
| EBIT (TTM) | -378.94M | |||
| Net Income (TTM) | -322.30M | |||
| Net Income Avl. to Common (TTM) | -322.30M | |||
| Total Revenue Growth (Q YOY) | 35.57% | |||
| Earnings Growth (Q YOY) | -69.18% | |||
| EPS Diluted (TTM) | -2.90 | |||
| EPS Diluted Growth (Q YOY) | -0.13% | |||
| Balance Sheet | RNA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 1.50B | |||
| Cash Per Share (Q) | $11.69 | |||
| Total Current Assets (Q) | 1.54B | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 1.42B | |||
| Current Ratio (Q) | 15.735 | |||
| Book Value Per Share (Q) | $11.89 | |||
| Total Assets (Q) | 1.56B | |||
| Total Current Liabilities (Q) | 98.02M | |||
| Total Debt (Q) | 6.80M | |||
| Total Liabilities (Q) | 138.94M | |||
| Total Common Equity (Q) | 1.42B | |||
| Cash Flow | RNA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -854.20M | |||
| Cash from Financing (TTM) | 1.19B | |||
| Net Change in Cash (TTM) | 37.29M | |||
| Levered Free Cash Flow (TTM) | -197.47M | |||
| Cash from Operations (TTM) | -300.87M | |||
